Illumina Revenue and Competitors

Location

$28M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Illumina's estimated annual revenue is currently $4.3B per year.(i)
  • Illumina's estimated revenue per employee is $384,236
  • Illumina's total funding is $28M.
  • Illumina's current valuation is $63.3B. (January 2022)

Employee Data

  • Illumina has 11139 Employees.(i)
  • Illumina grew their employee count by -4% last year.

Illumina's People

NameTitleEmail/Phone
1
Sr IT EngineerReveal Email/Phone
2
Staff ScientistReveal Email/Phone
3
Senior Manager, Government AffairsReveal Email/Phone
4
General CounselReveal Email/Phone
5
Sr. Staff Program ManagerReveal Email/Phone
6
Senior Director Clinical BioinformaticsReveal Email/Phone
7
Associate Director, Business OperationsReveal Email/Phone
8
Senior Finance Director, MarketingReveal Email/Phone
9
Associate Director EngineeringReveal Email/Phone
10
Manager, Design Quality and Transfer EngineeringReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$224.5M89138%N/AN/A
#2
$459.2M25085%$242.6M$11.6B
#3
$121.6M8529%$1.3B$2.7B
#4
$7.2M36N/AN/AN/A
#5
$1.5M17N/AN/AN/A
#6
$119.4M659N/AN/AN/A
#7
$230.5M124052%$338.8M$3B
#8
$7.2M55N/AN/AN/A
#9
$168.6M860N/AN/AN/A
#10
$142.9M704N/AN/AN/A
#11
$950.2M2366-25%$511.5MN/A
#12
$1.5M17N/AN/AN/A
#13
$5.2M45N/AN/AN/A
#14
$5M32N/AN/AN/A
#15
$157.9M77831%N/AN/A
#16
$281.5M1135-7%$411.9M$6.1B
#17
$4.2M36N/AN/AN/A
#18
$229.8M681N/AN/AN/A
#19
$4.3M37N/AN/AN/A
#20
$29.3M190N/AN/AN/A
Add Company

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

keywords:N/A

$28M

Total Funding

11139

Number of Employees

$4.3B

Revenue (est)

-4%

Employee Growth %

$63.3B

Valuation

N/A

Accelerator

Illumina News

2022-04-20 - CSRWire - Illumina Supports Leading German Hospital to ...

Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children. Hannover Medical School study will...

2022-04-20 - 2 Reasons to Buy Illumina, and 1 Reason to Sell

Illumina (ILMN 1.85%) leads the genome sequencing industry with a 90% market share in the U.S. and a 75% share globally.

2022-04-20 - 2 Reasons to Buy Illumina, and 1 Reason to Sell

Illumina (ILMN 1.85%) leads the genome sequencing industry with a 90% market share in the U.S. and a 75% share globally.

2022-04-20 - CSRWire - Illumina Supports Leading German Hospital to ...

Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children. Hannover Medical School study will...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2244.6M11452-1%N/A
#2
$3892.1M1224713%N/A
#3
$2551.5M126947%N/A
#4
$5011.1M132577%N/A
#5
$2753.9M135662%N/A